Botanix Pharmaceuticals is a dermatology company developing novel treatments for common skin diseases and infections | $BOT
$BOT
Joined July 2016
- Tweets562
- Following532
- Followers1.1K
- Likes153
$BOT released Q1 Quarterly Reports. Sofdra shipments grew to 35,130. Botanix initiated decisive cost actions to preserve cash runway.
View Reports - buff.ly/tiBW3Wo
$BOT #ASX #dermatology #pharmaceuticals #pharma #biotech #innovation #hyperhidrosis
REGISTER NOW | Join BOT executives for our Quarterly Activity and 4C Quarterly Cash Flow Webinar on 27 October at 11:00 am AEDT / 8:00 am AWST for an important update.
Click to pre-register - buff.ly/d7HMPAg
$BOT #ASX #dermatology #pharmaceuticals #pharma #biotech
$BOT The FY2026 Annual Report has been released, reflecting the first full year of Sofdra’s launch. Total prescriptions shipped for Sofdra (sofpironium) grew to 105,794 in FY2026.
buff.ly/BroWtIj
$BOT #ASX #dermatology #pharmaceuticals #pharma #biotech #innovation
Botanix Pharmaceuticals (ASX:BOT) released the recording of our recent investor webinar with our Executive Team. We shared insights on the Quarterly Activity Report, 4C Cash Flow Report, and a Sofdra® update.
📺 Watch video - youtu.be/9o67NKD8S80
$BOT.ax
$BOT.ax released Q4 Quarterly Reports. Sofdra quarterly shipments grew 25% to 33,358 and hit a record 12,895 shipments in June.
View Reports - buff.ly/xpu5rJ9
REMINDER: Quarterly Update Webinar on Today!
Join our executive team for the Company’s Quarterly Activity Report and 4C Quarterly Cash Flow Report Webinar on 27 July at 11:00 am AEST / 9:00 am AWST for an important update.
Register via - buff.ly/jJ1Zvf3
$BOT #ASX
📆 Quarterly Update Webinar | Registration Open
Join our executive team for the Company’s Quarterly Activity Report and 4C Quarterly Cash Flow Report Webinar on 27 July at 11:00 am AEST / 9:00 am AWST for an important update.
Click to pre-register: janemorganmanagement-au.zoom…
Notice of Allowance for US patent on Sofdra® drug substance
This protects Sofdra’s crystalline form & preparation method from unauthorised commercial manufacturing into May 2040.
View Release: app.sharelinktechnologies.co…
$BOT #ASX #dermatology #pharma
Botanix (ASX:BOT) received an Intention to Grant from the European Patent Office for its sofpironium topical gel applicator. Once validated, this IP protection runs until May 2039—giving ~13 more years of runway!
Read more: stocksdownunder.com/botanix-…
$BOT.ax #ASX #dermatology
$BOT: The European Patent Office has issued an Intention to Grant for EP 19799730.7. This covers the proprietary applicator tech for our sofpironium topical gel (Sofdra®).
Read more: buff.ly/bYu5vvz
$BOT released Q3 Quarterly Reports. Total prescriptions shipped continued on an upward trajectory, with March the highest-shipment month for Sofdra® (sofpironium).
View the reports here: bit.ly/4n7zCU3
REGISTER NOW | Join company executives for our Quarterly Activity and 4C Quarterly Cash Flow Webinar on 29 April at 10.30 am AEST / 8.30 am AWST for an important update.
Click to pre-register: botanixpharma.zoom.us/webina…
$BOT released Q2 Quarterly Reports. Compared to Q1, total prescriptions for Sofdra® grew 24% to 25,351, and net revenue increased 28% to $9.1 million.
Read the reports here: bit.ly/4qH4jAp
$BOT #ASX #dermatology #pharmaceuticals#pharma #biotech#innovation #hyperhidrosis
📆 REGISTER NOW | Join company executives for our Quarterly Activity and 4C Quarterly Cash Flow Webinar on 27 January at 10.30 am AEDT / 7.30 am AWST for an important update.
Click to pre-register: us06web.zoom.us/webinar/regi…
$BOT thanks valued shareholders and other significant contributors to the success of Sofdra(sofpironium) in the Chairman’s Address presented at the Annual General Meeting.
View ASX Release: bit.ly/48lWMQK
$BOT Three Sofdrascientific posters were accepted and exhibited at dermatology continuing medical education (CME) conferences. CME is a trusted source for dermatologists.
Read the full story: bit.ly/4qS4REa
